|Podcasts|July 12, 2022

Diversity in Clinical Trials—It Takes a Village

Author(s)Lisa Henderson, Andy Studna, Senior Editor

Catharine Grimes, Senior Director, Bristol Myers Squibb Foundation, discusses the goal to increase diversity in clinical trials through the BMS Foundation Diversity in Clinical Trials Career Development Award Program, the Foundation's Global Cancer Disparities Initiative, and more.

Listen to the latest Pharmaceutical Commerce podcast

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner

ByAndy Studna, Senior Editor

August 20th 2026

ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

ByAndy Studna, Senior Editor

August 19th 2026

ACT Brief: TrialBlazer Timeline Reductions and Operational Demands, Structural Trial Collaboration and Site Integration, and Henlius-Sandoz Biosimilars Partnership

ByAndy Studna, Senior Editor

August 18th 2026

ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma

ByAndy Studna, Senior Editor

August 17th 2026

ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced

ByAndy Studna, Senior Editor

August 14th 2026

Diversity in Clinical Trials—It Takes a Village

Related Content

ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner

ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

ACT Brief: TrialBlazer Timeline Reductions and Operational Demands, Structural Trial Collaboration and Site Integration, and Henlius-Sandoz Biosimilars Partnership

ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma

ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced

Trending on Applied Clinical Trials Online

Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations

When the Slack Runs Out: AI and the CRO Operating Model

What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to Succeed

ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment

ACT Brief: AI Literacy and Ecosystem Adoption Requirements, CRO Operating Models Under Agentic AI Pressure, and Platform Collaborations in Vaccine and Antibody Discovery